{"filings":[{"id":869720,"accession_number":"0001193125-26-257978","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2026-06-04T23:41:10+00:00","items":["5.07"],"status":"ready","headline":"LeMaitre Vascular 2026 annual meeting results; director John Roush gets 29% withheld votes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Two Class II directors elected: David B. Roberts (18.9M for, 1.25M withheld) and John A. Roush (14.2M for, 5.9M withheld).","Advisory vote on executive compensation approved: 19.3M for, 0.8M against, 13.6K abstain.","Ratification of Grant Thornton as auditor for 2026 approved: 21.2M for, 108.5K against.","Total shares present/proxy: 21.3M of 22.8M outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91589,"accession_number":"0001193125-26-206578","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q1 2026 sales $66.6M (+11%), EPS $0.68 (+42%); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $66.6M (up 11% YoY, 10% organic); gross margin 72.7% (+350 bps); EPS $0.68 (+42%).","Operating income $17.8M (+41%), op margin 27%; cash grew to $367.2M.","Artegraft grew 36% worldwide; records for grafts (+20%), valvulotomes (+15%), carotid shunts (+11%).","Quarterly dividend $0.25/share (payable June 4, record May 21); $100M share repurchase program active.","FY 2026 guidance: sales $277-283M (mid $280M, +12%), EPS $2.93-3.08 (mid $3.00, +26% adj.)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":66551000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91588,"accession_number":"0001193125-26-153779","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"LeMaitre Vascular director Bridget Ross not standing for re-election; board rebalanced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bridget Ross will not stand for re-election as Class II director at June 2, 2026 Annual Meeting, serving until term ends; no disagreement with company.","David B. Roberts nominated as Class II director; will resign Class I directorship contingent on election, to rebalance board classes.","Board reduced from eight to seven members effective upon Ms. Ross's departure and Mr. Roberts' class transfer.","Post-meeting board composition: 2 Class I, 2 Class II, 3 Class III directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101792,"accession_number":"0001193125-26-071954","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q4 2025 sales $64.5M (+16%), EPS $0.68 (+39%), raises dividend 25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 sales $64.5M (+16% YoY, +15% organic); diluted EPS $0.68 (+39%).","Gross margin 71.7% (+240 bps); operating income $18.8M (+47%).","Quarterly dividend increased 25% to $0.25/share; payable March 26, 2026 to holders of record March 12, 2026.","Board authorized $100M share repurchase program, expiring February 18, 2027.","FY2026 guidance: sales mid $280M (+12%), adj. op. income +21%, adj. EPS +22%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":249602000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118113,"accession_number":"0001193125-25-270458","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K/A","filed_at":"2025-11-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LeMaitre Vascular Board adopts annual say-on-pay votes after stockholder preference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted at June 2, 2025 annual meeting for annual say-on-pay frequency.","Board determined to hold future advisory say-on-pay votes every year.","No other changes to the original Form 8-K filed June 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118114,"accession_number":"0001193125-25-269454","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q3 sales $61.0M (+11%), EPS $0.75 (+54%); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 sales $61.0M (+11% YoY, +12% organic); Grafts +23%, Shunts +18%, Artegraft +33%.","GAAP diluted EPS $0.75 (+54%); adjusted EPS $0.62 (+27%).","Adjusted gross margin 70.8% (up 300 bps) on pricing and manufacturing efficiencies.","Full-year 2025 guidance raised: sales $247-249M, EPS $2.48-2.53 (midpoint +30%).","Quarterly dividend $0.20/share, payable Dec 4 to holders of record Nov 20."],"consensus_eps_estimate":null,"consensus_eps_actual":1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":185149000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134569,"accession_number":"0001437749-25-024862","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Vascular Q2 sales up 15% to $64.2M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 EPS $0.60 (+16% YoY); sales $64.2M (+15% organic) driven by catheters (+27%) and grafts (+19%).","Gross margin 70.0% (+110 bps); operating income $16.1M (+12%).","Full-year guidance raised: sales $248-$254M (midpoint +14%), EPS $2.23-$2.37 (midpoint +19%).","Quarterly dividend of $0.20/share declared, payable Sept 4, 2025 to holders of record Aug 21.","Cash increased $16.9M sequentially to $319.5M; $75M share repurchase program active through Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":124103000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151425,"accession_number":"0001437749-25-019314","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LeMaitre Vascular holds 2025 annual meeting; all four proposals approved by stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected three Class I directors: LeMaitre (18.4M for, 1.6M withheld), Roberts (18.2M for, 1.8M withheld), Shadan (15.2M for, 4.8M withheld).","Advisory vote on executive compensation passed with 19.1M for, 0.9M against, 36.6K abstain.","Stockholders selected '1 year' frequency for future advisory votes on executive compensation (16.99M for).","Ratified Grant Thornton LLP as independent auditor for 2025 with 21.0M for, 43K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151424,"accession_number":"0001437749-25-014093","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Vascular Q1 sales $59.9M (+12% YoY), raises FY guidance, declares $0.20 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $59.9M, +12% reported (+13% organic); EPS $0.48, +10% YoY.","FY 2025 sales guidance raised to $242-249M (mid $245M, +13% organic) from prior $239M.","Quarterly dividend of $0.20/share declared, payable May 29 to holders of record May 15.","Artegraft received MDR CE Mark on April 29; European launch to begin.","Ended Elutia porcine patch distribution agreement on April 30 (U.S. hospital sales $5.0M in 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":59871000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170304,"accession_number":"0001437749-25-005495","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q4 sales $55.7M (+14%), EPS $0.49 (+30%), raises dividend 25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $55.7M (+14% organic), EPS $0.49 (+30%), op income $12.9M (+26%).","Quarterly dividend increased 25% to $0.20/share, payable March 27 to March 13 record date.","Board authorized $75M share repurchase program through Feb 2026.","Issued $172.5M 2.50% convertible notes due 2030 in Dec 2024, net proceeds $167.7M.","FY2025 guidance: sales $239.1M mid (+9%, +10% organic), EPS $2.24 mid (+16%)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":219863000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170303,"accession_number":"0001437749-25-003679","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LeMaitre Vascular appoints Dorian LeBlanc as CFO; base salary $565,000, target bonus $225,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dorian LeBlanc appointed CFO effective March 10, 2025; previously CFO at LumiraDx (acquired by Roche).","Annual base salary $565,000; target performance bonus $225,000; annual equity award $375,000 (4-year vesting).","One-time RSU grant of $100,000 with 4-year vesting; eligible for 401(k) match, 25 vacation days.","Severance: $100,000 if termination without cause before Mar 10, 2028; after, greater of 2 weeks' salary per year or $225,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187309,"accession_number":"0001104659-24-130155","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"LeMaitre Vascular issues $172.5M of 2.50% convertible notes due 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $150M principal amount plus $22.5M from initial purchasers' option exercise.","Notes bear interest at 2.50% per annum, mature Feb 1, 2030.","Initial conversion price ~$119.73 per share, convertible into common stock at company's election.","Notes unsecured senior obligations; net proceeds for working capital, general purposes, potential acquisitions.","Issued under Rule 144A; shares upon conversion exempt under Section 3(a)(9)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187308,"accession_number":"0001104659-24-129159","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LeMaitre Vascular prices $150M convertible senior notes offering","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$150M aggregate principal of 2.50% Convertible Senior Notes due 2030, interest payable semi-annually.","Initial conversion price ~$119.73/share, ~30% premium over $92.10 closing price on Dec. 16, 2024.","Net proceeds ~$145.9M (or ~$167.8M if initial purchasers fully exercise $22.5M greenshoe).","Proceeds to be used for working capital, general purposes, and potential acquisitions.","Notes are senior unsecured; redeemable by company after Feb. 5, 2028 under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187307,"accession_number":"0001104659-24-128674","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LeMaitre Vascular announces $150M convertible senior notes offering due 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offering of $150M aggregate principal amount of Convertible Senior Notes due 2030.","Initial purchasers granted option to buy up to an additional $22.5M in notes.","Notes mature Feb 1, 2030, convertible into cash, stock, or combination at company's election.","Proceeds for working capital and general purposes, including potential acquisitions.","Private offering to qualified institutional buyers under Rule 144A; not registered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187306,"accession_number":"0001437749-24-032784","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Vascular Q3 sales up 16% to $54.8M, EPS $0.49 (+46%), raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 sales $54.8M (+16% organic); diluted EPS $0.49, +46% YoY.","Gross margin 67.8% (+280 bps) on price increases and manufacturing efficiencies.","Full-year guidance raised: sales $219-221M, op margin 24%, EPS $1.91-1.96.","Quarterly dividend of $0.16/share declared, payable Dec 5 to holders of record Nov 21.","Cash increased $10.8M sequentially to $123.9M; $50M share repurchase program ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":164146000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203814,"accession_number":"0001437749-24-027754","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Joseph P. Pellegrino Jr. to retire effective March 7, 2025; remains on Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pellegrino will retire as employee and CFO on March 7, 2025, after 2024 10-K filing; stays on Board until June 2027.","Company to conduct search for replacement CFO; Pellegrino to assist in hiring and onboarding.","Reaffirms August 1, 2024 financial guidance for Q3 and full-year 2024.","Pellegrino served 19 years as executive; was re-elected to Board in June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203813,"accession_number":"0001437749-24-024304","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q2 EPS $0.52 +44%, FY guidance raised; dividend $0.16","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $55.8M +11% (+12% organic); EPS $0.52 +44% vs Q2 2023.","Gross margin 68.9% (+490 bps); operating income $14.4M +52%.","Allografts +30%, bovine patches +12%, carotid shunts +22% led growth.","Q3 guidance: sales $52.7-54.7M, EPS $0.42-0.46; FY guidance raised to sales $218.8M, EPS $1.82-1.91.","Quarterly dividend $0.16/share payable Aug 29, record Aug 15."],"consensus_eps_estimate":null,"consensus_eps_actual":0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":109327000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220414,"accession_number":"0001437749-24-019032","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Director Jasinski fails to win majority vote at annual meeting; board rejects resignation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lawrence J. Jasinski received 8.28M for vs 11.31M withheld, triggering resignation policy; board rejected resignation on June 3.","Shareholders approved amendment to stock option plan, authorizing 1,000,000 new shares for issuance.","Advisory vote on executive compensation approved (19.12M for, 0.62M against).","Ratification of Grant Thornton LLP as auditor for 2024 approved (20.64M for, 0.09M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220413,"accession_number":"0001437749-24-014372","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Vascular Q1 sales $53.5M (+14%), EPS $0.44 (+62%); raises FY op. margin guidance to 22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net income $9.9M (+64%); gross margin 68.6% (+300 bps) on price increases and manufacturing efficiencies.","Allografts (+31%), carotid shunts (+27%), and APAC sales (+44%) led growth; organic sales +11%.","Board declared $0.16/share dividend payable May 30 to holders of record May 16.","FY 2024 guided sales $212.7-217.3M (+11%), EPS $1.73-1.84 (+33% vs. FY 2023), operating margin 22%.","Share repurchase program of up to $50M authorized through Feb 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":53478000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240056,"accession_number":"0001437749-24-005732","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q4 sales $48.9M (+19%), EPS $0.38 (+49%); declares $0.16 dividend, $50M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 sales $48.9M (+19% YoY), net income $8.5M (+50%), EPS $0.38 (+49%).","Gross margin 68.1% (+450 bps) driven by ASP increases and manufacturing efficiencies.","Segment highlights: allografts +52%, bovine patches +18%, EMEA sales +21%.","Full year 2024 guidance: sales $209.7-$214.3M (midpoint +10%), EPS $1.60-$1.71.","Board declares $0.16/share dividend (payable Mar 28) and authorizes $50M share buyback."],"consensus_eps_estimate":null,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":193484000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257568,"accession_number":"0001437749-23-029792","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"LeMaitre Q3 sales $47.4M (+21%); EPS $0.33; declares $0.14 dividend; guides Q4 $48-50M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 sales $47.4M (+21% YoY, +16% organic); net income $7.5M (+38%); diluted EPS $0.33 (+36%).","Gross margin 65.0% (+80 bps); operating income $9.2M (+49%); cash up $6.8M to $97.0M.","Q4 2023 guidance: sales $48-50M, EPS $0.34-0.38; full-year 2023 EPS $1.30-1.35 (+42% YoY).","Quarterly dividend $0.14/share, payable Nov 30 to shareholders of record Nov 16.","Leases for Burlington, MA headquarters extended to Dec 31, 2034 with escalating rent; no renewal options."],"consensus_eps_estimate":null,"consensus_eps_actual":0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":144601000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274914,"accession_number":"0001437749-23-021414","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q2 sales up 19% to $50.1M; EPS $0.36 (+127%); FY23 guidance raised; $0.14 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $50.1M, +19% (+16% organic) vs Q2 2022; operating income $9.5M (+63%).","Net income $8.1M (+130%), diluted EPS $0.36 (+127%); adjusted EPS +25%.","Gross margin 64.0% (down from 66.0%); EMEA +26%, APAC +21%, Americas +16%.","FY23 guidance: sales $193M–$197.8M (+21%/+18% organic), EPS $1.23–$1.34 (ex-special $1.25–$1.35).","Quarterly dividend $0.14/share, payable Aug 31, record Aug 17; $25M buyback authorized."],"consensus_eps_estimate":null,"consensus_eps_actual":0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":97190000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292272,"accession_number":"0001437749-23-016676","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LeMaitre Vascular announces 2023 annual meeting voting results","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bridget A. Ross elected as Class II director with 14,649,999.71 votes for, 4,496,976 withheld.","John A. Roush elected as Class II director with 18,526,479.71 votes for, 620,496 withheld.","Advisory vote on executive compensation approved: 18,603,555.38 for, 524,894 against.","Ratification of Grant Thornton LLP as auditor for 2023 approved: 20,105,297.71 for, 92,675 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292271,"accession_number":"0001437749-23-012106","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q1 sales up 22% organic to $47.1M; EPS flat at $0.27; issues guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $47.1M, +19% (+22% organic); net income $6.0M flat; diluted EPS $0.27 (-1%).","Valvulotomes (+29%), carotid patches (+17%), bovine grafts (+22%), allografts (+42%), carotid shunts (+18%) led record Q1 sales.","Q2 2023 guidance: sales $47.1M–$49.5M; EPS $0.30–$0.35. Full year: sales $187.1M–$193.1M; EPS $1.14–$1.27.","Quarterly dividend $0.14/share, payable June 1, 2023 to holders of record May 17, 2023.","Agreed to distribute Aziyo porcine cardiac patches in US for three years (option to acquire); Aziyo's 2022 US patch sales $6.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":47075000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312976,"accession_number":"0001437749-23-004378","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q4 sales up 8% organic; EPS $0.25 (-9%); dividend raised 12% to $0.14; $25M buyback authorized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $41.0M (+4% reported, +8% organic); net income $5.6M (-9%); EPS $0.25 (-9%).","Gross margin 63.6% vs 65.7% (150 bps FX headwind); op income $7.0M (-16%).","Quarterly dividend raised 12% to $0.14/share, payable March 23 to record March 9.","Board authorized $25M share repurchase program through Feb 21, 2024.","Q1 2023 guidance: sales $42.6-45.0M (mid +11% reported, +13% organic); EPS $0.22-0.27."],"consensus_eps_estimate":null,"consensus_eps_actual":0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":161651000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331497,"accession_number":"0001437749-22-024955","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q3 sales $39M (+2%), EPS $0.25 (-17%); declares $0.125 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 sales $39.0M (+2% reported, +7% organic YoY); EPS $0.25 diluted, down 17%.","Q3 operating income $6.2M, -32%; net income $5.5M, -16%.","Full-year 2022 guidance: sales $160.5M-$162.9M; EPS $0.91-$0.97 (ex-special $1.02-$1.08).","Quarterly dividend of $0.125/share, payable Dec 1, 2022 to holders of record Nov 17.","Appointed Martha Shadan as independent director, effective Sept 21, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":120697000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349024,"accession_number":"0001437749-22-022937","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2022-09-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LeMaitre Vascular appoints Martha Shadan to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to eight seats; Martha Shadan appointed as Class I director effective Sept 21, 2022.","Director term expires at 2025 annual meeting; no material interests or arrangements.","Compensation per standard Non-Employee Director Policy: $26k cash retainer, $112k equity grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349023,"accession_number":"0001437749-22-018011","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Vascular Q2 sales $42.1M (+8% organic); raises FY guidance to 10% organic growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 sales $42.1M (+4%, +8% organic); reported EPS $0.16 (-60%); adjusted EPS ex-special charge $0.29 (-26%).","Operating income $5.8M (-48%); ex-$3.1M special charge from closing St. Etienne factory, op income $8.9M (-20%).","FY 2022 guidance raised: sales $162.7M-$165.3M (mid $164M, +10% organic); op income ex-special $32.7M-$34.4M.","Board declared $0.125 quarterly dividend, payable Sept 8 to holders of record Aug 25; $20M share repurchase program ongoing.","Operational milestones: Seoul office opened, French factory closed, Chinese XenoSure cardiac approval filed, Omniflow II CE Mark received."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":81669000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365855,"accession_number":"0001437749-22-014260","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LeMaitre Vascular shareholders elect two Class I directors, approve say-on-pay, ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["George W. LeMaitre elected with 16,025,727.6 votes for; David B. Roberts with 17,820,028.6 votes for; both serve three-year terms until 2025.","Advisory vote on executive compensation approved with 18,995,635.6 shares for, 223,867 against, and 1,033,299 broker non-votes.","Ratification of Grant Thornton as auditor for 2022 approved with 20,271,264.6 votes for, 2,242 against, 10,183 abstaining."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365854,"accession_number":"0001437749-22-010106","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"LeMaitre Q1 sales $39.6M (+13% organic), EPS $0.27; guides FY $160-164M, closes French factory","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $39.6M, +10% YoY (+13% organic); net income $6.0M, +2%; EPS $0.27, -4%.","FY 2022 guidance: sales $160-164M (+5%/+8% org), EPS $1.10-$1.20; lowered due to stronger USD.","Quarterly dividend $0.125/share, payable June 2, 2022 to shareholders of record May 17, 2022.","Committed to close St. Etienne, France factory by June 30, 2022; ~$3.1M special charges in 2022, ~$1M annual op income benefit from 2023.","Agreed to buy out Korean distributor JiSang for $540k; direct-to-hospital in Korea starting January 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":39561000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385369,"accession_number":"0001437749-22-004329","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q4 2021 revenue $39.5M (+5%), EPS $0.28 (-18%); raises dividend 14%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 sales $39.5M (+5% YoY); net income $6.2M (-12%); diluted EPS $0.28 (-18%).","Quarterly dividend raised 14% to $0.125/share, payable Mar 24 to holders of record Mar 8.","Board authorizes $20M share repurchase program through Feb 22, 2023.","FY 2022 guidance: sales $162-166M, EPS $1.35-1.45 (midpoint +12% vs 2021).","Cash and investments $70M at year-end, up $2.9M during Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":154424000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403240,"accession_number":"0001437749-21-027707","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2021-12-02T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"LeMaitre Vascular terminates $65M credit facility; records $0.5M non-cash charge","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Terminated Credit Agreement with KeyBank and Truist; no borrowings outstanding at termination.","Recorded one-time non-cash charge of ~$0.5M from unamortized deferred financing costs.","Charge was not included in prior Q4/full-year 2021 guidance released Oct 28.","Elimination of ~$50K quarterly expenses (cash + non-cash) beginning Q1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403239,"accession_number":"0001437749-21-024532","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q3 sales $38.4M (+5% organic), EPS $0.30 (-19%), declares $0.11 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $6.5M (-13%), op. income $9.1M (-9%), gross margin 64.8% (+250 bps).","Cash & investments $67.1M after $58.7M stock offering; Artegraft debt paid off.","Q4 guidance: sales $39–41M (midpoint +7%), EPS $0.29–0.34 (-8% midpoint).","Quarterly dividend $0.11/share, payable Dec 2 to holders of record Nov 19.","Americas and EMEA grew 5% each, APAC up 16%; Delta variant deferred elective surgeries."],"consensus_eps_estimate":null,"consensus_eps_actual":0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":114921000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422171,"accession_number":"0001437749-21-021311","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2021-09-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"LeMaitre Vascular assumes EU MDR CE Mark responsibility for CardioCel/VascuCel; costs deducted from $2M earn-out","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On August 28, 2021, LeMaitre amended its 2019 asset purchase agreement with Anteris Technologies (formerly Admedus).","LeMaitre will seek CE Mark certification under EU MDR for CardioCel and VascuCel biologic patches.","Costs of obtaining CE Mark approvals will be deducted from the $2 million earn-out payable to Anteris.","75% of earn-out paid after CardioCel MDR certification; 25% after VascuCel MDR certification.","Transition services agreement extended by nine months to July 11, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422170,"accession_number":"0001437749-21-018520","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"LeMaitre Vascular secures full exercise of underwriters' option for 150k shares at $54.50","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Underwriters fully exercised option to purchase 150,000 additional common shares on August 4, 2021.","Additional shares sold at $54.50 per share, matching the initial offering price.","Total offering now 1.15M shares, generating ~$62.7M in gross proceeds.","Underwriting agreement dated July 13, 2021 with Jefferies and Stifel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422169,"accession_number":"0001437749-21-017888","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2021-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q2 2021 sales $40.7M (+64% YoY), EPS $0.40; declares $0.11 dividend; FY21 guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $40.7M (+64% or +35% organic); operating income $11.1M (+128%); net income $8.3M (+137%); diluted EPS $0.40 (+131%).","Gross margin 65.8% vs 68.5% in Q2 2020; decline driven by product mix, manufacturing inefficiencies, and inventory write-downs.","Quarterly dividend of $0.11/share approved, payable Sept 9, 2021 to record holders on Aug 26, 2021.","FY 2021 guidance: sales $154.1M–$158.1M (+21% YoY at midpoint), EPS $1.30–$1.40 (+30% at midpoint).","Completed $54.5M follow-on stock offering on July 16; $23.0M net proceeds used to repay long-term debt."],"consensus_eps_estimate":null,"consensus_eps_actual":0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":76553000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422168,"accession_number":"0001437749-21-017080","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2021-07-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"LeMaitre Vascular closes public offering of 1M shares at $54.50, netting ~$51M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,000,000 shares at $54.50 per share; underwriters have 30-day option for up to 150,000 additional shares.","Net proceeds of approximately $51.0 million after underwriting discounts and offering expenses.","Directors and executive officers subject to 90-day lock-up on sale of Common Stock.","Underwriting agreement with Jefferies LLC and Stifel, Nicolaus & Company as representatives.","Offering closed on July 16, 2021; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422167,"accession_number":"0001437749-21-016848","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2021-07-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"LeMaitre Q2 net sales $40.7M (+64%), op income up ~128%; launches stock offering, receives CE marks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 preliminary net sales $40.7M (+64% reported, +35% organic vs Q2 2020).","Operating income ~$10.9-11.3M, up ~128% at midpoint vs Q2 2020.","Gross margin 65.5-66.1%, down 2.7pp at midpoint due to inventory write-downs and manufacturing inefficiencies.","Commenced underwritten public offering of common stock; proceeds to repay $23M debt and for general corporate purposes.","Received renewed CE marks for five vascular products expiring 2024; XenoSure indications narrowed (no neuro/cardiac)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":76553000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422166,"accession_number":"0001437749-21-016726","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2021-07-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LeMaitre Vascular increases CEO annual equity to $1.1M, raises executive salaries for 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO annual equity value increased from $725k to $1.1M; other NEOs: Pellegrino $250k->$500k, Roberts $250k->$500k, Kamke $115k->$225k.","2022 cash compensation approved: CEO salary rises to $568,498 (from $473,470) with bonus target $333,880; similar increases for other NEOs.","New equity grants will be 50% stock options, 25% RSUs, and 25% performance stock units.","Compensation Committee adopted Eighth Amended and Restated Equity Award Grant Policy formalizing grant process and levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}